(1.30%) 5 114.22 points
(0.65%) 38 333 points
(2.34%) 15 976 points
(0.36%) $83.87
(-3.11%) $1.587
(0.24%) $2 348.10
(-0.34%) $27.26
(0.22%) $922.50
(0.35%) $0.935
(0.70%) $11.03
(0.16%) $0.801
(-0.30%) $91.89
Live Chart Being Loaded With Signals
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...
Stats | |
---|---|
Today's Volume | 290 776 |
Average Volume | 544 070 |
Market Cap | 11.60B |
EPS | DKK0 ( 2024-03-05 ) |
Next earnings date | ( DKK0.460 ) 2024-05-07 |
Last Dividend | DKK0 ( N/A ) |
Next Dividend | DKK0 ( N/A ) |
P/E | 7.75 |
ATR14 | DKK0.112 (0.08%) |
Volume Correlation
Bavarian Nordic A/S Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bavarian Nordic A/S Correlation - Currency/Commodity
Bavarian Nordic A/S Financials
Annual | 2023 |
Revenue: | DKK7.06B |
Gross Profit: | DKK4.52B (64.07 %) |
EPS: | DKK19.23 |
FY | 2023 |
Revenue: | DKK7.06B |
Gross Profit: | DKK4.52B (64.07 %) |
EPS: | DKK19.23 |
FY | 2022 |
Revenue: | DKK3.15B |
Gross Profit: | DKK1.70B (53.99 %) |
EPS: | DKK-4.93 |
FY | 2021 |
Revenue: | DKK1.90B |
Gross Profit: | DKK570.32M (30.05 %) |
EPS: | DKK-8.60 |
Financial Reports:
No articles found.
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators